EXenatide Study of Cardiovascular Event Lowering (Ongoing)
The EXenatide Study of Cardiovascular Event Lowering (EXSCEL) clinical trial will find out if giving people with type 2 diabetes a drug called Exenatide alongside their usual diabetes care regime can reduce their risk of heart disease.
EXSCEL is a phase IIIb/IV multinational trial, being conducted in around 30 countries across Australasia, Asia, Europe, North America and Latin America.
Coordinated by DTU and Duke Clinical Research Institute (DCRI), and sponsored by Amylin Pharmaceuticals LLC, (a wholly owned subsidiary of Bristol-Myers Squibb) the trial began in June 2010.
14,000 people with type 2 diabetes aged 18 years or older whose HbA1c is between 6.5% and 10% will be recruited to the trial. Each participant will receive an injection of study medication (Exenatide/Placebo) once a week, and will be followed for a minimum of four years.
We expect that results of this pragmatic trial (which aims to measure how beneficial a treatment would be in real clinical practice) will be available in 2018.